CSO Anders Sandberg interviewed in BioStock on the development in Alzheimer's research
Alzinova AB (publ) ("Alzinova" or the "Company") announces today that Chief Scientific Officer (CSO) Anders Sandberg is interviewed in a recent article in BioStock where he shares his scientific reflections on the latest developments in the industry.
Anders Sandberg, Chief Scientific Officer at Alzinova with many years of experience in protein research with an emphasis on neurotoxic peptide aggregates, is Alzinova's CSO and co-founder of the Company. BioStock contacted Sandberg to learn more about how new research findings are impacting the success of Alzheimer's research and what sets Alzinova apart from other companies in the industry.
Read the full interview, in Swedish, here:https://www.biostock.se/2022/10/alzinovas-cso-om-marknaden-och-framtiden-for-alzheimerforskningen/
Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.
For more information, please contact:
Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The Company’s Certified Advisor on Nasdaq First North Growth Market is Corpura info@corpura.se +46 768-532 822. For more information about Alzinova, please visit: www.alzinova.com